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Abstract 
Prostaglandins are ephemeral, infinitesimal signallers self-regulating every cell in the body, including those sub-serving mood and 
immunity. At first, they were perceived as a master switch, but now are believed to regulate every component of cellular micro-anatomy 
and physiology, including those of the organelles, cytoskeleton, proteins, enzymes, nucleic acids and mitochondria. Prostaglandins are 
responsible, paradoxically, for cell function and dysfunction. Excessive prostaglandin synthesis depresses immune function and may 
induce cancer. An ideal anti-cancer agent would inhibit prostaglandins in such a manner as to shut down the pathogenesis of cancer. In 
this paper, I will show that antidepressants have such properties. 
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The anti-prostaglandin, immunostimulating 
and antimicrobial properties of lithium and 
antidepressants 
Depression predisposes us to, among other things, infection, 
cancer, osteoporosis, and neurodegenerative, cardiovascular and 
auto-immune disorders [1,2]. Excessive syntheses of 
prostaglandins is incriminated in all of these [1,2]. Lithium and 
antidepressants have potent anti-prostaglandin, immunostimulating 
and antimicrobial properties, and antidepressants have the 
paradoxical ability to mitigate, reverse or induce auto-immunity 
[1,2]. 
When synthesized excessively, prostaglandin E2 depresses 
cellular and humoral immunity, allowing pathogens to replicate 
3. Prostaglandins regulate the physiology, immunity, replication 
and toxicity of micro-organisms and the resistance of their hosts 
[1–4]. Failure of non-steroidal anti-inflammatory drugs in 
infections led to the conclusion that inhibiting prostaglandins 
has limited value in that field. The prostaglandin-inhibiting 
properties of lithium and antidepressants have been neglected 
[5–10], along with their unique immunopotentiating and 
antimicrobial actions [2]. In the early 1950s, clinicians observed 
that patients treated for tuberculosis with the monoamine 
oxidase inhibitors isoniazid and iproniazid had an elevation of 
mood and energy. It was also observed that monoamine 
oxidase inhibitors have dual anti-tuberculosis and 
antidepressant properties failed to impact the pharmacology of 
infectious disorders. Remission of such manifestations of viral 
infections as sinusitis, sinobronchitis, frequent colds, sore 
throats, cold sores and genital herpes in patients taking lithium 
carbonate has been reported [11–13]. The polymorphonuclear 
leukocytes of a 29-year-old woman with eczema and recurrent 
staphylococcal and streptococcal skin infections were 
unresponsive to standard chemotactic stimuli. In vitro addition of 
lithium to her polymorphonuclear preparations restored their 
chemotactic response. After receiving lithium carbonate, 1 g/d 
for five weeks, she became free of infection and relapsed when 
lithium was withdrawn [14]. Lithium chloride prevents replication 
of type 1 and 2 herpes virus in cell culture [15] and augments 
several in vitro immune reactions [16]. 
Monoamine oxidase inhibitors can reverse tuberculosis, 
aphthous ulcers, cold sores, genital herpes, upper respiratory 
tract infections and plantar warts [17–19]. Tricyclic 
antidepressants can reverse aphthous ulcers [20], reduce the 
frequency of recurrences of shingles [1,2], remit the pain of this 
disorder [1,2], prevent post-herpetic neuralgia [1,2], destroy 
leishmania minor and major in vitro [21], and inhibit in vitro 
growth of the intestinal parasite giardia lamblia [22]. Tricyclic 
antidepressants have anti-malarial properties: they enhance in 
vitro susceptibility of Plasmodium falciparum to chloroquine and 
are lethal in vitro against Trypanasoma parasites [23-27]. 
Selective serotonin re-uptake inhibitors can destroy such fungi 
in vitro as Candida and Aspergillus [28], reverse recurrent 
vulvovaginal candidiasis in vivo [29], have anti-microbial activity 
[30] and are synergistic when combined with antibiotics [31]. 
Impaired lymphocyte function reduced natural killer cell activity, 
reduced lymphocyte responses to mitogens and decreased 
natural killer cell populations have been demonstrated in 
depressives [1,2,32,33]. Tricyclic antidepressants augment 
natural killer cell activity in vivo and in vitro [34] and the 
monoamine oxidase inhibitor tranylcypromine enhances 
defective cell-mediated immunity [35]. As lithium and 
antidepressants have immunopotentiating properties, they are 
effective against a wide range of micro-organisms. Evidence to 
date shows that while lithium has antiviral and antibacterial 
properties, antidepressants have antiviral, antibacterial, 
antiparasitic and fungicidal properties. Response of infection to 
lithium and antidepressants mirrors that of response to 
depression, with subjects responding selectively to 
antidepressants or lithium; antidepressants are highly specific 
and humans remarkably variable. Response of depression and 
infection to lithium or an antidepressant is usually simultaneous, 
suggesting that the central actions of the drugs are important. 
While antivirals are not necessarily immunostimulants, lithium 
and antidepressants are invariably antivirals. If antidepressants 
double as antibiotics, it would not be surprising if antibiotics 
doubled as antidepressants. Many antibiotics, among them 
clarithromycin, erythromycin, amoxacillin and ciprofloxacin, can 
elevate mood to the level of hypomania or mania [36]. 
 
Prostglandins in carcinogenesis 
Among the mechanisms of carcinogenesis are up-regulation of 
cyclo-oxygenase, oncogene synthesis and expression, viral 
activation, signal disruption, accelerated cell replication, failed 
apoptosis, tumour initiation and promotion, angiogenesis, 
metastasis, immunosuppression, auto-immunity and activation 
of mitochondria. All fall within the orbit of prostaglandins and 
their forming enzymes. In 1968, Williams reported high levels of 
prostaglandins in the thyroid and plasma of patients with 



















medullary cancer of the thyroid [37]. In 1976, Goodwin reported 
excessive synthesis of prostaglandin E2 in suppressor T-cells of 
patients with Hodgkin’s disease [38]. Numerous studies have 
confirmed elevated levels of prostaglandins in solid tumours and 
in the immune cells and body fluids of cancer patients [39,40]. 
The isolation of such isoforms of cyclo-oxygenase as COX-2 
[41], and the synthesis of selective COX-2 inhibitors has 
stimulated research into the expression of this isoform in cancer 
and its role in apoptosis. COX-2 is up-regulated in such cancers 
as those of the head and neck, breast, lung, pancreas, bladder, 
cervix, prostate and mesothelium [41–43]. In population studies, 
chronic use of such prostaglandin inhibitors as aspirin and 
ibuprofen has reduced the risk of colon cancer by as much as 
40% [44]. 
Armato and Andreis showed that arachidonic acid and 
prostaglandins F1 alpha and F2 alpha stimulate the DNA-
synthetic and mitotic activities of hepatocytes [45]. Goodlad has 
reported that the increase in gastric mucosal mass induced by 
misoprostol in the stomach of dogs is due to increased cell 
production. The increase in mucosal mass was the result of a 
dramatic increase in the foveolar surface mucous cells [46], 
other studies show a paradoxical, inhibitory effect of 
prostaglandins on DNA synthesis [47]. Prostaglandins and their 
synthesizing enzymes are key factors in many signalling events, 
and disruptions of signalling pathways have been incriminated 
in many cancers. 
In her pioneering studies, Karmali [48,49] showed that 
increased thromboxane formation in human breast cancer 
specimens is associated with three clinical variables: tumour 
size, axillary lymph node metastases and distant metastases. 
The mechanisms by which prostaglandins and thromboxanes 
induce metastasis include induction of proteolytic enzyme 
production, neovascularization and subversion of the immune 
response. The initiation of metastasis is thought to involve the 
adherence of circulating tumour cells to endothelial cells or to 
basement membranes. Prostaglandins and thromboxanes play 
a role in adherence [49,50], with local thromboxane 
concentrations possibly determining the sites of metastasis [51]. 
Immunosuppression is a cause and effect of cancer. Increase in 
prostaglandins at the primary tumour focus may block 
surveillance by the immune system, while an increase in plasma 
prostaglandins may contribute to the suppressive environment 
for lymphocyte function [52]. 
In a paradoxical counterpoint to immunosuppression, numerous 
autoimmune phenomena are reported in patients with cancer 
[53]. Malignant tumours are diagnosed with increased frequency 
in patients with such autoimmune disorders as pemphigus, 
Myasthenia gravis and the Eaton-Lambert syndrome [54,55]. 
The paraneoplastic syndrome includes a variety of neurological, 
haematological, metabolic, cardiovascular and dermatological 
disorders, in all of which prostaglandins have been incriminated 
[55,56]. As monoamine oxidase inhibitors, originally used in the 
treatment of tuberculosis, have potent antiviral and 
immunostimulating properties, it is not surprising that one of 
them, Matulane (procarbazine), is effective in treating stage 111 
and 1V Hodgkin’s disease. 
 
Depression: A precursor of cancer 
In the Ward Jones lecture given at Manchester University in 
1957, Sir Heneage Ogilvie commented, ‘I have slowly come to 
frame in my mind an aphorism that can never be stated as 
such, because no statistics can be advanced to support it: “The 
happy man never gets cancer” … The instances where the first 
recognisable onset of cancer has followed almost immediately 
on some disaster, bereavement, the breakup of a relationship, a 
financial crisis, or an accident are so numerous that they 
suggest that some controlling force that has hitherto kept the 
outbreak … in check has been removed’ [57]. In 1998, Penninx 
et al at the National Institute of Aging provided compelling data 
for Ogilvie’s hypothesis: chronically depressed people over the 
age of 70 are 88% more likely to develop cancer and twice as 
likely to die of it than their mellow peers [58]. 
 
Antineoplastic properties of antidepressants 
in vitro 
Many studies show that antidepressants have potent anti-
cancer properties, both in vitro and in vivo, with regard to 
various antidepressants, mechanisms of action and cancer cell 
types [59–78]. Irrespective of their putative mechanism of 
action, the antidepressants destroyed the cells or arrested their 
proliferation [59–78]. Hydroxyprostaglandin dehydrogenase is 
the primary prostaglandin-degrading enzyme, highly expressed 
in normal colon mucosa but lost in human colon cancers 
[79,80]. Lack of this enzyme promotes the earliest steps of 
growth of benign as well as malignant colon tumours [79,80]. 
When this enzyme was first characterized, every agent tested in 
the hope of stimulating it either had no effect or inhibited it. 
Eventually Mak and Chen showed that amitriptyline and 
imipramine powerfully activate the enzyme in mice, especially 
the kidney enzyme, with more than a thousand-fold activation 
by amitriptyline. Amitriptyline and imipramine had potent 
activating effects on this enzyme in the brain [81]. 



















Mitochondria, prostaglandins and 
antidepressants 
Mitochondria are tiny organelles that supply cellular energy and 
are involved in signalling, cellular differentiation, control of the 
cell cycle, growth and programmed cell death. The cells of 
malignant gliomas of the brain, and small and non-small cell 
cancers of the lung, tend to repair DNA-breaks caused by 
radiation and chemotherapy. In an effort to accomplish cell 
death by an alternative method, investigators are targeting 
mitochondria. Small molecule agents known as ‘mitocans’ are 
able to enter tumour cell mitochondria, reduce oxygen 
consumption, and activate mechanisms leading to cell death. 
Agents that can destroy cancer cells in this manner, while 
leaving normal cells intact, notably include antidepressants [82-
84]. Laboratory experiments using this approach on various 
cancer cells, including those of gliomas, are encouraging 
[65,66]. It goes without saying that prostaglandins are 
intermediaries between mitocans and mitochondria [85–87]. 
 
Antineoplastic properties of antidepressants 
in vivo 
A woman suffering from major depression and advanced liver 
cancer (hepatoma) was treated with psychotherapy, the 
antidepressant fluvoxamine (Luvox), glycyrrhizin acid and 
dehydroepiandrosterone (DHEA). Various indices of defective 
immune function normalized, and her liver function tests 
improved. At follow-up two-and-a-half years later, she was well 
and symptom free [88]. In 1990, a 60-year-old woman had a 
mastectomy for inflammatory breast cancer, followed by 
excision of infiltration of the chest wall. She was given a 
prognosis of less than a year. I treated her with various 
antidepressants, and when relocating in 2003 she was in 
apparent good health. 
A middle-aged man had a two-year history of recurrent 
glioblastoma multiforme of the cerebellum, resistant to all 
conventional therapies. Within a week of starting sertraline, he 
noticed an appreciable reduction in tremor and ataxia. After 
taking the antidepressant for three weeks, he was virtually free 
of these symptoms. 
Discussion 
It would seem that antidepressants have the potential to arrest, 
prevent, reverse and palliate cancer. Short of that they have 
many other uses in cancer care. Antidepressants can reduce 
the severity and frequency of hot flashes in patients treated with 
chemotherapy for breast cancer, and venlafaxine (Effexor), and 
remit acute neurosensory symptoms secondary to oxaliplatin 
chemotherapy [89]. The monoamine oxidase inhibitors deprenyl 
and clorgyline protect nonmalignant human cells from ionising 
radiation and chemotherapy toxicity [90], and such 
antidepressants as nefadazone are capable of reversing 
chemotherapy-induced vomiting [91]. 
As the response to antidepressants is highly specific, many 
patients require multiple trials before responding. Some 
subjects are refractory to all antidepressants, and some relapse 
due to tachyphylaxis [92]. Prostaglandins are capable of 
paradoxically inducing pro- and anti-cancer actions. The 
omnipresence of paradox warns that antidepressants are 
capable of initiating or accelerating cancer. Maintaining an index 
of suspicion, close clinical observation and limiting the duration 
of drug trials can mitigate such paradox. Epidemiological 
studies have failed to confirm the suspicion that antidepressants 
may induce breast cancer [93]. However, breast cancer has 
been reported in three men, taking selective serotonin re-uptake 
inhibitors [94]. 
Wherever prostaglandin-synthesizing enzymes convert 
arachidonic acid or phospholipids to prostaglandins, there are 
possible sites of action of antidepressants. By maintaining these 
enzymes within physiological limits, antidepressants shut down 
the mechanisms of carcinogenesis. Considerable evidence now 
shows that antidepressants are cytotoxic and cytostatic; convert 
multidrug resistant cells to sensitive and protect nonmalignant 
cells from ionizing radiation and chemotherapy [95]. While 
lithium has immunostimulating and anti-microbial properties, 
there is little evidence for its possible antineoplastic actions. 
Antidepressants have potent analgesic properties alone or as 
potentiators of narcotics, and they enhance sleep, appetite and 
occasionally energy. Their immunostimulating and anti-microbial 
properties are relevant to infection secondary to chemotherapy 
or radiation. Alleviation of anxiety, depression, recrimination and 
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